TCRs In Personalized Oncology With BlueSphere Bio's Keir Loiacono
Business Of Biotech
00:00
The Preclinical Pipeline Strategy for TCRT Cell Therapy
We have a lead indication, which is high risk leukemia, AML, ALL, and MDS. We will likely be adding a third development program to bridge between the first and second. And then on the further end of our pipeline, we have a fully, what will be a fully personalized TCRT cell therapy program directed to solid tumors. So after I start at the beginning, you know, we're targeting high risk leukemia,. It's like you have two separate pipelines almost, right? That's how it feels.
Transcript
Play full episode
